

Endothelin-1 and Gastrointestinal Bleeding: A Predictor for Clinical Outcomes

✉ Muhammed Fatih TUTUNCU¹, ✉ Bahaeddin ONUR¹, ✉ Hakan Barış DEMIRBAS¹
¹Primary Health Care Corporation, Doha, Qatar

To the Editor

I read the article prepared by Alparslan and Baykan, titled “Evaluation of Glasgow-Blatchford, Rockall Scores and Shock Index of Patients Admitted from the Emergency Department with A Diagnosis of Upper Gastrointestinal System Bleeding” distributed in the sixth volume and second issue of your journal with great interest (1). I congratulate the authors and the editorial board for the article investigating predictive ability for mortality by analyzing shock indices together with Glasgow Blatchford Scoring and Rockall Scoring, which are used in upper gastrointestinal bleeding.

Gastrointestinal bleeding has an important place in the management of surgical or medical critical patients in emergency department practice. Multidisciplinary management with emergency medicine specialist, gastroenterologist, general surgeon, interventional radiologist is the cornerstone of the management (2-4). Although significant progress has been made in stroke management and stroke teams have been established (5), local protocols are used in the management of gastrointestinal bleeding (4). Unfortunately, local protocols are usually shaped by transfusion outside of office hours. Therefore, parameters that will reveal the urgency of the patients and the necessity of endoscopic or radiological or surgical intervention are needed. Vital parameters and scoring systems have been frequently studied in this field. In gastrointestinal bleeding studies, unlike emergency medicine practice (mortality, morbidity), the outcome of the necessity of endoscopic intervention has been studied (6-9). In this article, we would like to talk about the gastrointestinal bleeding study of Endothelin-1 (ET-1), a previously known molecule (10).

ET-1 is a potent vasoconstrictive peptide primarily produced by endothelial cells lining blood vessels. It plays a crucial role in the regulation of vascular tone, blood pressure, and cardiovascular homeostasis. ET-1 is part of

the endothelin peptide family, which includes ET-2 and ET-3, though ET-1 is the most biologically active and widely studied member (11).

The synthesis of ET-1 is stimulated by factors such as hypoxia, shear stress, and pro-inflammatory cytokines. It acts through two specific G-protein coupled receptors: endothelin receptor type A (ETA) and endothelin receptor type B (ETB). ETA receptors are mainly found on vascular smooth muscle cells and mediate vasoconstriction, while ETB receptors are located on endothelial cells, promoting vasodilation through nitric oxide and prostacyclin release (12,13).

Beyond vascular tone regulation, ET-1 is implicated in various pathophysiological processes, including hypertension, heart failure, pulmonary arterial hypertension (PAH), and atherosclerosis. Elevated ET-1 levels are often observed in these conditions and are associated with poor prognosis. ET-1 also has pro-inflammatory, proliferative, and fibrotic effects, contributing to vascular remodeling and organ damage over time (14).

Given its broad role in cardiovascular diseases, ET-1 and its receptors are therapeutic targets. Endothelin receptor antagonists, such as bosentan and ambrisentan, have been developed to treat PAH and other cardiovascular disorders, underscoring ET-1's significance in disease mechanisms and treatment strategies (15).

Current literature showed that elevated ET-1 plasma levels in cirrhosis contribute significantly to portal hypertension by regulating portal vein pressure and sinusoidal endothelial structure (16,17). Based on this data Wagih Shaltout et al. speculated that ET-1 can be a predictor of intervention on esophageal variceal bleeding (10). They investigated the role of ET-1 levels as a noninvasive predictor of early esophageal variceal rebleeding within 5 days following endoscopic variceal ligation (EVL). The study included 50 patients with liver cirrhosis and portal hypertension due to hepatitis C virus infection. The results revealed that elevated

serum ET-1 levels were significant predictors of early rebleeding. Specifically, an ET-1 cutoff level of 65.29 was found to have 88.2% specificity, 87.5% sensitivity, and 88% accuracy in predicting rebleeding. They recommended that serum endothelin-1 levels provide a practical and reliable noninvasive method for predicting early variceal rebleeding, which is a serious complication. Moreover, ET-1 levels correlated with comorbidities, such as kidney dysfunction and the length of hospital stay, highlighting its clinical importance in managing patients after EVL.

As a conclusion ET-1 could be a predictor in gastrointestinal bleeding. Researchers should be encouraged to investigate the association of ET-1 with gastrointestinal bleeding.

References

- Alpaslan M, Baykan N. Evaluation of Glaskow-Blatchford, Rockall Scores and Shock Index of Patients Admitted from the Emergency Department with A Diagnosis of Upper Gastrointestinal System Bleeding. *Eurasian j Crit Care*. September 2024;6(2):51-57. doi:10.55994/ejcc.1532796
- Orpen-Palmer J, Stanley AJ. Update on the management of upper gastrointestinal bleeding. *BMJ Med*. 2022 Sep 28;1(1):e000202. doi: 10.1136/bmjmed-2022-000202.
- Erten M, Sevimli H, Akça HŞ, Algın A, Özdemir S, Eroğlu SE. A Rare Cause of Gastrointestinal Hemorrhage: Secondary Aortoenteric Fistula. *Abant Med J*. 2020;9(2):65-8.
- Baugh CW, Sodickson AD, Kivlehan SM, Chen PC, Perencevich ML, Jesudian AB. A Novel Multidisciplinary Team Activation for Patients with Severe Gastrointestinal Bleeding: Creation of the Code GI Bleed Protocol. *Clin Exp Gastroenterol*. 2023 Apr 26;16:55-58. doi: 10.2147/CEG.S404247.
- Akça HŞ, Algın A, Özdemir S, Kolbaş F, Yılmaz E, Diler Y, Eroğlu SE. Effect of telestroke practices on short-term mortality in ischemic stroke patients. *J Contemp Med*. January 2022;12(1):127-133. doi:10.16899/jcm.973616
- Orpen-Palmer J, Stanley AJ. A Review of Risk Scores within Upper Gastrointestinal Bleeding. *J Clin Med*. 2023 May 26;12(11):3678. doi: 10.3390/jcm12113678
- Özkan A, Özsviri K, Özdemir S, Coşkun A. Validation of the Japan score in patients with upper gastrointestinal system bleeding and comparison with other scores. *Ann Clin Anal Med* 2023;14(9):854-8; DOI: 10.4328/ACAM.21834
- Boustany A, Alali AA, Almadi M, Martel M, Barkun AN. Pre-Endoscopic Scores Predicting Low-Risk Patients with Upper Gastrointestinal Bleeding: A Systematic Review and Meta-Analysis. *J Clin Med*. 2023 Aug 9;12(16):5194. doi: 10.3390/jcm12165194
- Yönak H, Özdemir S, Kokulu K, Akça HŞ, İslam MM, Algın A, Yunusov M, Eroğlu SE. Are AIMS65 and glasgow-blatchford scores useful in predicting health costs in patients admitted to emergency department with acute upper gastrointestinal bleeding: a prospective and observational study. *J Exp Clin Med*. May 2021;38(3):326-330.
- Wagih Shaltout S, Messery AE, Elshabrawi A, I Amin A, H Elshennawy M, Ibrahim Mortada M, ElSherbiny W, Elalfy H, Elhammady D. Can Endothelin-1 Levels in Patients with Esophageal Variceal Bleeding at Admission Predict Rebleeding Within 5 Days? *Turk J Gastroenterol*. 2024 Feb;35(2):136-142. doi: 10.5152/tjg.2024.23028.
- Nishiyama SK, Zhao J, Wray DW, Richardson RS. Vascular function and endothelin-1: tipping the balance between vasodilation and vasoconstriction. *J Appl Physiol* (1985). 2017 Feb 1;122(2):354-360. doi: 10.1152/jappphysiol.00772.2016.
- Kowalczyk A, Kleniewska P, Kolodziejczyk M, Skibska B, Goraca A. The role of endothelin-1 and endothelin receptor antagonists in inflammatory response and sepsis. *Arch Immunol Ther Exp (Warsz)*. 2015 Feb;63(1):41-52. doi: 10.1007/s00005-014-0310-1.
- Freeman BD, Machado FS, Tanowitz HB, Desruisseaux MS. Endothelin-1 and its role in the pathogenesis of infectious diseases. *Life Sci*. 2014 Nov 24;118(2):110-9. doi: 10.1016/j.lfs.2014.04.021.
- Haryono A, Ramadhiani R, Ryanto GRT, Emoto N. Endothelin and the Cardiovascular System: The Long Journey and Where We Are Going. *Biology (Basel)*. 2022 May 16;11(5):759. doi: 10.3390/biology11050759.
- Nahar S, Kanda S, Chatha U, Odoma VA, Pitliya A, AlEdani EM, Bhangu JK, Javed K, Manshahia PK, Yu AK. Current Status of Endothelin Receptor Antagonists in Pulmonary Arterial Hypertension: A Combined Study Results and Pharmacology-Based Review. *Cureus*. 2023 Jul 31;15(7):e42748. doi: 10.7759/cureus.42748.
- Angus PW. Role of endothelin in systemic and portal resistance in cirrhosis. *Gut*. 2006 Sep;55(9):1230-2. doi: 10.1136/gut.2005.088633.
- Møller S, Emmeluth C, Henriksen JH. Elevated circulating plasma endothelin-1 concentrations in cirrhosis. *J Hepatol*. 1993 Sep;19(2):285-90. doi: 10.1016/s0168-8278(05)80584-7.